Olema Oncology (Nasdaq: OLMA) granted stock options to eight new employees to purchase an aggregate of 215,800 shares of common stock, effective July 1, 2026, as inducement awards under its 2022 Inducement Plan in line with Nasdaq Listing Rule 5635(c)(4).
Options have a 10-year term, a per-share exercise price of $12.08, and vest over four years, subject to continued employment.
Olema’s latest disclosure details 215,800 inducement stock options at an exercise price of $12.08, c...
Analysis
Olema’s latest disclosure details 215,800 inducement stock options at an exercise price of $12.08, continuing its 2022 Inducement Plan usage. Investors may track how such grants accumulate over time and interact with already moderate short interest.
Key Figures
Inducement option shares:215,800 sharesNew employees:8 employeesExercise price:$12.08 per share+5 more
8 metrics
Inducement option shares215,800 sharesAggregate options granted to eight new employees effective July 1, 2026
New employees8 employeesRecipients of inducement stock option grants
Exercise price$12.08 per shareEqual to last reported sale price on July 1, 2026
Option term10 yearsTerm of inducement stock options
Initial vesting25%Portion vesting on first anniversary of vesting commencement date
Subsequent vesting schedule36 monthly installmentsRemaining vesting over following three years
Pre-headline share price$12.64Price prior to inducement grant announcement
52-week range$4.1206–$36.2591Pre-headline 52-week low and high
Reported higher net loss alongside sizable cash and securities balance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent headlines often saw shares slip on generally positive or neutral catalysts, with a stronger decline around earnings but a single notable bounce on conference participation news.
Regulatory & Risk Context
Short Interest: 15.06%
Short Interest
15.06% of float
0%15%30%+
moderateas of 2026-06-15Days to cover: 7.88
Short positioning was moderately elevated, implying scope for sharper swings if sentiment shifts quickly in response to news or trading flows.
Key Terms
nasdaq listing rule 5635(c)(4), stock options, exercise price, inducement plan
4 terms
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
stock optionsfinancial
"granted stock options to eight new employees to purchase an aggregate of 215,800 shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise pricefinancial
"a 10-year term and an exercise price of $12.08 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
inducement planfinancial
"granted under the Company's 2022 Inducement Plan as an inducement material"
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
SAN FRANCISCO, July 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to eight new employees to purchase an aggregate of 215,800 shares of the Company's common stock, effective as of July 1, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates.The stock options have a 10-year term and an exercise price of $12.08 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on July 1, 2026. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact Courtney O’Konek Vice President, Corporate Communications Olema Oncology media@olema.com
FAQ
What did Olema Oncology (OLMA) announce on July 2, 2026 about stock options?
Olema Oncology announced inducement stock option grants covering 215,800 shares to eight new employees. According to Olema, the options were granted under its 2022 Inducement Plan as material inducements to employment, consistent with Nasdaq Listing Rule 5635(c)(4).
How many Olema Oncology (OLMA) shares are covered by the new inducement stock options?
The new inducement stock options cover an aggregate of 215,800 Olema common shares. According to Olema, these options were granted to eight new employees and are subject to the terms of the company’s 2022 Inducement Plan and standard vesting conditions.
What is the exercise price and term of the new Olema Oncology (OLMA) stock options?
The inducement stock options have an exercise price of $12.08 per share and a 10-year term. According to Olema, the price equals the last reported Nasdaq sale price of its common stock on July 1, 2026.
How do the Olema Oncology (OLMA) inducement stock options vest for new employees?
The stock options vest over four years for each new employee. According to Olema, 25% vests on the first anniversary of the vesting commencement date, with the remaining 75% vesting in 36 equal monthly installments, subject to continuous employment.
Why did Olema Oncology (OLMA) use Nasdaq Listing Rule 5635(c)(4) for these stock option grants?
Olema used Nasdaq Listing Rule 5635(c)(4) to grant options as inducement awards for new hires. According to Olema, these options were a material inducement to employment and were issued under the separate 2022 Inducement Plan approved by the board’s Compensation Committee.
Who approved the July 2026 Olema Oncology (OLMA) inducement stock option grants?
The inducement stock option grants were approved by the Olema board’s Compensation Committee. According to Olema, the committee authorized the options under the 2022 Inducement Plan as part of hiring incentives for eight new employees joining the clinical-stage oncology company.
